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While the paradigm that malignancies arise through a
stepwise progression from benign precursors has been
established for many malignancies, it remains unclear if
this holds true for ovarian cancer. Serous ovarian carci-
nomas are the predominant clinically important subtype
and it has been widely believed that some or all of these
arise from precursors derived from the ovarian surface
epithelium, such as inclusion cysts or serous benign and
borderline tumours. Despite the co-occurrence of
benign, borderline and low grade carcinoma epithelial
components, direct molecular evidence for the benign
lesions as precursors is limited. This study aimed to per-
form high resolution copy number analysis using a ser-
i e so fb e n i g ns e r o u so v a r i a nt u m o u r st oi d e n t i f ya n y
underlying genomic changes indicative of early events in
tumourigenesis, which could assist in determining if
these lesions represent precursors to some invasive ser-
ous ovarian carcinomas. This is the first ultra-high reso-
lution copy number analysis of benign serous tumours
of the ovary.
High resolution copy number analysis was performed
on tumour epithelial and fibroblast DNA using the Affy-
metrix OncoScan and SNP6.0 array platforms. Copy
number aberrations (CNAs) were detected in the epithe-
lium of only 5.6% (2/35) of serous cystadenomas and
cystadenofibromas. Unexpectedly, CNAs were detected
in the tumour fibroblasts in 36% (14/39) of cases,
including gain of chromosome 12 in 10 cases. No KRAS
or BRAF mutations were detectable in either component
of the benign serous tumours. Chromosome 12 trisomy
has been previously identified in pure fibromas,
supporting the concept that a significant proportion of
benign serous tumours are in fact primary fibromas
with an associated cystic mass. This study therefore pro-
vides a novel perspective on the development of these
tumours.
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